Drugs / PL54
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07672756 | Jul 2025 → Jun 2027 expected | phenylketonuria | Chongqing Peg-Bio Biopharm Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PL54 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07672756 ↗ |
| Modality | Protein / enzyme biologic | “PEGylated Recombinant Phenylalanine Ammonia-Lyase” NCT07672756 ↗ |
| Route | Subcutaneous | “single or multiple subcutaneous injections of PL54 injection” NCT07672756 ↗ |